SBIR-STTR Award

Motion Compensated Brain Pet Imaging for Neuroscience Research
Award last edited on: 9/14/2017

Sponsored Program
SBIR
Awarding Agency
NIH : NIDA
Total Award Amount
$1,500,000
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
David M Beylin

Company Information

Brain Bio (AKA: Brain Biosciences Inc)

9700 Great Seneca Highway Unit 320
Rockville, MD 20850
   (240) 426-6021
   info@brain-bio.com
   www.brain-bio.com
Location: Single
Congr. District: 08
County: Montgomery

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2015
Phase I Amount
$911,987
?Advanced imaging technologies such as Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MR) have led to remarkable improvement in our knowledge of brain metabolism, function, and biochemistry. And yet, our understanding of most neurological disorders is at best rudimentary. Etiology of such common diseases as drug and alcohol addiction, schizophrenia, Alzheimer's dementia and Parkinson's remains elusive. Malignant brain tumors such as glioblastoma continue being fatal. Changes happening in the brain in such common syndromes as hospital-acquired delirium, and post-operative cognitive decline, are not understood. Most studies involving advanced brain imaging remain small due to logistical challenges, cost constraints, and difficulty of scanning neurological patients in standard radiology equipment. Acceleration of brain research is required to elucidate the pathophysiology of neurological and psychiatric conditions. Brain Biosciences was established to make neurological imaging comfortable, inexpensive, and widely available both in the clinic and in the research laboratory. One of the common problems encountered in imaging research is unintentional patient motion. Head movement during Positron Emission Tomography (PET) degrades PET image quality, leads to image artifacts, and introduces quantitative errors. Motion is particularly common in confused patients with neurological diseases, drug addiction, and movement disorders. This problem becomes especially relevant as research involving lengthy dynamic scans, and high-resolution brain imaging becomes common. While sedation is often used to minimize the patient motion, sedative drugs change brain biochemistry, interfere with radiopharmaceutical uptake, and may cause side effects. Physical restraints are often distressing, and may increase patient agitation. In this direct Phase II SBIR proposal we seek to develop, clinically validate, and receive FDA clearance for FREEMotion(tm), a video-based head tracking system, enabling motion- compensated brain Positron Emission Tomography (PET) imaging of neurological patients without sedation or physical head restraint.

Public Health Relevance Statement:


Public Health Relevance:
This application proposes to develop and validate a novel head tracking system capable of compensating for patient motion during high-resolution brain Positron Emission Tomography (PET) imaging. This device will lower improve the quality, comfort, and quantification of brain PET in patients with neurological and psychiatric diseases, as well as drug abuse. The proposed device will have applications both in the clinic and neuroscience research.

NIH Spending Category:
Bioengineering; Brain Cancer; Brain Disorders; Cancer; Clinical Research; Diagnostic Radiology; Drug Abuse (NIDA only); Mental Health; Neurosciences; Rare Diseases; Substance Abuse

Project Terms:
Acceleration; Accounting; Adoption; Adverse effects; Agitation; Alcohol dependence; Algorithms; Alzheimer's Disease; base; Biochemistry; Brain; Brain imaging; brain metabolism; brain research; Calibration; Certification; Clinic; Clinical; Clinical Data; Clinical Research; commercialization; Computer Vision Systems; cost; Delirium; design; Devices; Disease; Distress; Drug abuse; Drug Addiction; Electromagnetics; Equipment; Etiology; Evaluable Disease; experience; Face; Failure (biologic function); Financial compensation; Freedom; Functional disorder; Funding; Glioblastoma; Guidelines; Head; Head Movements; Hospitals; Image; Imaging technology; Immune; Impaired cognition; improved; Institutional Review Boards; Knowledge; Laboratory Research; Lighting; Magnetic Resonance Imaging; Malignant neoplasm of brain; Maryland; medical schools; Mental disorders; Modeling; Morphologic artifacts; Motion; Motor Neuron Disease; Movement Disorders; nervous system disorder; Neurologic; Neurosciences Research; novel; Parkinson Disease; Participant; Patients; Pharmaceutical Preparations; Phase; Physical Restraint; Positioning Attribute; Positron-Emission Tomography; Postoperative Period; Procedures; programs; prototype; public health relevance; Qualifying; Quality Control; Radiology Specialty; Radiopharmaceuticals; Reader; reconstruction; Research; Resolution; restraint; Safety; Sales; Scanning; Schizophrenia; Sedation procedure; sedative; Small Business Innovation Research Grant; Software Design; Supervision; Syndrome; System; Testing; Universities; uptake; Vendor

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2016
Phase II Amount
$588,013
Advanced imaging technologies such as Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MR) have led to remarkable improvement in our knowledge of brain metabolism, function, and biochemistry. And yet, our understanding of most neurological disorders is at best rudimentary. Etiology of such common diseases as drug and alcohol addiction, schizophrenia, Alzheimer's dementia and Parkinson's remains elusive. Malignant brain tumors such as glioblastoma continue being fatal. Changes happening in the brain in such common syndromes as hospital-acquired delirium, and post-operative cognitive decline, are not understood. Most studies involving advanced brain imaging remain small due to logistical challenges, cost constraints, and difficulty of scanning neurological patients in standard radiology equipment. Acceleration of brain research is required to elucidate the pathophysiology of neurological and psychiatric conditions. Brain Biosciences was established to make neurological imaging comfortable, inexpensive, and widely available both in the clinic and in the research laboratory. One of the common problems encountered in imaging research is unintentional patient motion. Head movement during Positron Emission Tomography (PET) degrades PET image quality, leads to image artifacts, and introduces quantitative errors. Motion is particularly common in confused patients with neurological diseases, drug addiction, and movement disorders. This problem becomes especially relevant as research involving lengthy dynamic scans, and high-resolution brain imaging becomes common. While sedation is often used to minimize the patient motion, sedative drugs change brain biochemistry, interfere with radiopharmaceutical uptake, and may cause side effects. Physical restraints are often distressing, and may increase patient agitation. In this direct Phase II SBIR proposal we seek to develop, clinically validate, and receive FDA clearance for FREEMotion(tm), a video-based head tracking system, enabling motion- compensated brain Positron Emission Tomography (PET) imaging of neurological patients without sedation or physical head restraint.

Public Health Relevance Statement:


Public Health Relevance:
This application proposes to develop and validate a novel head tracking system capable of compensating for patient motion during high-resolution brain Positron Emission Tomography (PET) imaging. This device will lower improve the quality, comfort, and quantification of brain PET in patients with neurological and psychiatric diseases, as well as drug abuse. The proposed device will have applications both in the clinic and neuroscience research.

NIH Spending Category:
Bioengineering; Brain Cancer; Brain Disorders; Cancer; Clinical Research; Diagnostic Radiology; Drug Abuse (NIDA only); Mental Health; Neurosciences; Rare Diseases; Substance Abuse

Project Terms:
Acceleration; Accounting; Adoption; Adverse effects; Agitation; Alcohol dependence; Algorithms; Alzheimer's Disease; base; Biochemistry; Biological Sciences; Brain; Brain imaging; brain metabolism; brain research; Calibration; Certification; Clinic; Clinical; Clinical Data; Clinical Research; commercialization; Computer Vision Systems; cost; design; Devices; Disease; Distress; Drug abuse; Drug Addiction; Electromagnetics; Equipment; Etiology; Evaluable Disease; experience; Face; Failure; Financial compensation; Freedom; Functional disorder; Funding; Glioblastoma; Guidelines; Head; Head Movements; Health; Hospitals; Image; Imaging technology; Immune; Impaired cognition; improved; industry partner; Institutional Review Boards; Knowledge; Laboratory Research; Lighting; Magnetic Resonance Imaging; Malignant neoplasm of brain; Maryland; medical schools; Mental disorders; Modeling; Morphologic artifacts; Motion; Motor Neuron Disease; Movement Disorders; nervous system disorder; Neurologic; Neurosciences Research; novel; Parkinson Disease; Participant; Patients; Pharmaceutical Preparations; Phase; Physical Restraint; Positioning Attribute; Positron-Emission Tomography; postoperative delirium; Procedures; programs; prototype; Qualifying; Quality Control; Radiology Specialty; Radiopharmaceuticals; Reader; reconstruction; Research; Resolution; restraint; Safety; Sales; Scanning; Schizophrenia; Sedation procedure; sedative; Small Business Innovation Research Grant; Software Design; Supervision; Syndrome; System; Testing; Universities; uptake; Vendor